HighTower Advisors LLC Sells 11,189 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

HighTower Advisors LLC trimmed its position in Denali Therapeutics Inc. (NASDAQ:DNLI) by 30.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,138 shares of the company’s stock after selling 11,189 shares during the period. HighTower Advisors LLC’s holdings in Denali Therapeutics were worth $533,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DNLI. Wellington Management Group LLP increased its holdings in Denali Therapeutics by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock worth $312,491,000 after buying an additional 903,683 shares during the period. FMR LLC grew its position in shares of Denali Therapeutics by 3,234.3% in the third quarter. FMR LLC now owns 7,831,378 shares of the company’s stock valued at $228,128,000 after purchasing an additional 7,596,508 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Denali Therapeutics by 63.2% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock valued at $109,223,000 after acquiring an additional 1,451,770 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Denali Therapeutics by 13.8% during the 3rd quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock worth $36,076,000 after purchasing an additional 149,939 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Denali Therapeutics by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,028,462 shares of the company’s stock valued at $20,960,000 after acquiring an additional 12,652 shares during the last quarter. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Steve E. Krognes sold 3,339 shares of the business’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total transaction of $69,484.59. Following the transaction, the director now directly owns 25,757 shares of the company’s stock, valued at approximately $536,003.17. The trade was a 11.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Vicki L. Sato sold 3,080 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total value of $64,402.80. Following the sale, the director now owns 107,976 shares of the company’s stock, valued at $2,257,778.16. This represents a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 47,940 shares of company stock valued at $973,442 over the last quarter. Company insiders own 7.90% of the company’s stock.

Denali Therapeutics Stock Up 4.1 %

Shares of DNLI stock opened at $14.78 on Friday. The business has a fifty day simple moving average of $19.05 and a 200-day simple moving average of $23.23. Denali Therapeutics Inc. has a fifty-two week low of $13.67 and a fifty-two week high of $33.33. The stock has a market cap of $2.15 billion, a P/E ratio of -5.36 and a beta of 1.46.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.08. On average, sell-side analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on DNLI. Stifel Nicolaus raised shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a research note on Monday, December 16th. Morgan Stanley began coverage on shares of Denali Therapeutics in a research note on Friday, March 7th. They set an “overweight” rating and a $33.00 target price on the stock. JPMorgan Chase & Co. lowered their price objective on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a research report on Tuesday, January 7th. Oppenheimer decreased their price objective on shares of Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. Finally, Bank of America decreased their price target on shares of Denali Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, March 10th. Two analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Denali Therapeutics has an average rating of “Moderate Buy” and an average target price of $37.20.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.